TickerFiles

BioNexus Gene Lab Corp

Nasdaq · CIK 0001737523 · Fiscal year end 1231

BGLC

Latest reported period: Latest published period

Revenue

$22,842

Cost Of Revenue

$23,632

Gross Profit

$-790

Recent financials

MetricCurrentPriorChange
Revenue$22,842--
Cost Of Revenue$23,632--
Gross Profit$-790--
Operating Income$-540,490--
Net Income$-543,575--
Eps Diluted-0.225--
Total Assets$9.0M--
Total Liabilities$946,877--
Shareholders Equity$8.1M--
Operating Cash Flow$-147,671--
Capital Expenditures$325--

Latest filings

FormCompanyFiledAccession
10-QBioNexus Gene Lab Corp2026-05-150001477932-26-003242
10-KBioNexus Gene Lab Corp2026-04-140001477932-26-002218
10-QBioNexus Gene Lab Corp2025-11-140001477932-25-008343
10-QBioNexus Gene Lab Corp2025-08-180001477932-25-006023